Accrued portion of annual license fees.

No definition available.

Name:	bfrg_AccruedPortionOfAnnualLicenseFees
Namespace Prefix:	bfrg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Accrued annual license fee.

+ References

No definition available.

+ Details

Name:	bfrg_AccruedannualLicenseFee
Namespace Prefix:	bfrg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Annual license fee.

+ References

No definition available.

+ Details

Name:	bfrg_AnnualLicenseFee
Namespace Prefix:	bfrg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License maintenance fees.

+ References

No definition available.

+ Details

Name:	bfrg_AnnualLicenseMaintenanceFees
Namespace Prefix:	bfrg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Clinical Trial, Four Year Overall Survival Rate, Percentage

+ References

No definition available.

+ Details

Name:	bfrg_ClinicalTrialFourYearOverallSurvivalRatePercentage
Namespace Prefix:	bfrg_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Clinical Trial, Measurement Period

+ References

No definition available.

+ Details

Name:	bfrg_ClinicalTrialMeasurementPeriod
Namespace Prefix:	bfrg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Clinical Trial, Number of Patients Enrolled

+ References

No definition available.

+ Details

Name:	bfrg_ClinicalTrialNumberOfPatientsEnrolled
Namespace Prefix:	bfrg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Clinical Trial, Number of Patients Experiencing Adverse Effects

+ References

No definition available.

+ Details

Name:	bfrg_ClinicalTrialNumberOfPatientsExperiencingAdverseEffects
Namespace Prefix:	bfrg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Clinical Trial, Number of Patients Receiving Maximum Dose

+ References

No definition available.

+ Details

Name:	bfrg_ClinicalTrialNumberOfPatientsReceivingMaximumDose
Namespace Prefix:	bfrg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Clinical Trial, Two Year Overall Survival Rate, Percentage

+ References

No definition available.

+ Details

Name:	bfrg_ClinicalTrialTwoYearOverallSurvivalRatePercentage
Namespace Prefix:	bfrg_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Research and Development Period

+ References

No definition available.

+ Details

Name:	bfrg_CollaborativeArrangementResearchAndDevelopmentPeriod
Namespace Prefix:	bfrg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Term

+ References

No definition available.

+ Details

Name:	bfrg_CollaborativeArrangementTerm
Namespace Prefix:	bfrg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Increase decrease in sublicense percentage.

+ References

No definition available.

+ Details

Name:	bfrg_IncreaseDecreaseInSublicensePercentage
Namespace Prefix:	bfrg_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Payments for license fees after IPO.

+ References

No definition available.

+ Details

Name:	bfrg_LicenseFeePaymentMadeAfterIPO
Namespace Prefix:	bfrg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License initiation fee.

+ References

No definition available.

+ Details

Name:	bfrg_LicenseInitiationFee
Namespace Prefix:	bfrg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License payments.

+ References

No definition available.

+ Details

Name:	bfrg_LicensePayments
Namespace Prefix:	bfrg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Licensing Arrangement, Cure Period for Material Breach

+ References

No definition available.

+ Details

Name:	bfrg_LicensingArrangementCurePeriodForMaterialBreach
Namespace Prefix:	bfrg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Licensing Arrangement, Number of Patent Applications

+ References

No definition available.

+ Details

Name:	bfrg_LicensingArrangementNumberOfPatentApplications
Namespace Prefix:	bfrg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Licensing Arrangement, Number of Patents Issued

+ References

No definition available.

+ Details

Name:	bfrg_LicensingArrangementNumberOfPatentsIssued
Namespace Prefix:	bfrg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

MaterialAgreements

+ References

No definition available.

+ Details

Name:	bfrg_MaterialAgreementsLineItems
Namespace Prefix:	bfrg_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty on net sales.

+ References

No definition available.

+ Details

Name:	bfrg_PercentageOfRoyaltyOnNetSales
Namespace Prefix:	bfrg_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of sublicense.

+ References

No definition available.

+ Details

Name:	bfrg_SublicensePercentage
Namespace Prefix:	bfrg_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Upfront license fee.

+ References

No definition available.

+ Details

Name:	bfrg_UpfrontLicenseFee
Namespace Prefix:	bfrg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage of warrant issued.

+ References

No definition available.

+ Details

Name:	bfrg_WarrantIssuancePercentage
Namespace Prefix:	bfrg_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

+ References

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-6

+ Details

Name:	us-gaap_FiniteLivedPatentsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of cash paid for royalties during the current period.

+ References

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=bfrg_JHUAPLTechnologyLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bfrg_NewLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardTypeAxis=bfrg_FromTwoThousandAndTwentyThreeThroughTwoThousandAndTwentySevenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandTwentyTwoYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandTwentyThreeYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandTwentyFourYearAndBeyondMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_JulyTwoThousandTwentyThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandTwentyFiveYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandTwentySixYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandTwentySevenYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_JuneTwoThousandTwentySixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bfrg_InternallyDevelopmentDrugProjectsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=bfrg_OtherPartiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bfrg_GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bfrg_JohnsHopkinsUniversityMebendazoleLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandTwentyFourYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bfrg_JohnsHopkinsUniversityProdrugLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandTwentyEightYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandTwentyNineYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardDateAxis=bfrg_TwoThousandThirtyYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bfrg_LieberInstituteForBrainDevelopmentPartnershipMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bfrg_FeasibilityAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Material Agreements (Details)	1 Months Ended											6 Months Ended
Material Agreements (Details)	Mar. 31, 2026	Jun. 30, 2025 USD ($)	Sep. 30, 2023	Jul. 31, 2023 USD ($)	May 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	Oct. 31, 2022 USD ($)	Jul. 31, 2022 USD ($) shares	Feb. 28, 2022 USD ($) patient patent	Jan. 31, 2022 USD ($) patent	Feb. 28, 2018 patent	Jun. 30, 2026 USD ($)	Oct. 31, 2021
MaterialAgreements [Line Items]
Two year overall survival rate									41.70%
JHU-APL Technology License
MaterialAgreements [Line Items]
Number of issued patents \| patent											3
Number of patent applications \| patent											1
Warrant issuance percentage													5.00%
New License Agreement
MaterialAgreements [Line Items]
Issuance of common stock, net of issuance costs (in shares) \| shares								39,879
Collaborative arrangement termination cure period								60 days
New License Agreement \| From 2023 through 2027
MaterialAgreements [Line Items]
Finite-lived patents, gross					$ 275,000
New License Agreement \| 2022
MaterialAgreements [Line Items]
Royalty expense								$ 30,000
New License Agreement \| 2023
MaterialAgreements [Line Items]
Royalty expense								80,000
New License Agreement \| 2024 and Beyond
MaterialAgreements [Line Items]
Royalty expense								$ 300,000
New License Agreement \| July 2023
MaterialAgreements [Line Items]
License payments				$ 75,000
New License Agreement \| 2025
MaterialAgreements [Line Items]
License payments		$ 75,000
New License Agreement \| 2026
MaterialAgreements [Line Items]
License payments					75,000
New License Agreement \| 2027
MaterialAgreements [Line Items]
License payments					50,000
New License Agreement \| June 2026
MaterialAgreements [Line Items]
Accrued royalties												$ 150,000
Accrued annual license fee												4,167
Annual license fee												75,000
New License Agreement \| Maximum
MaterialAgreements [Line Items]
Sublicense percentage								50.00%
New License Agreement \| Minimum
MaterialAgreements [Line Items]
Sublicense percentage								25.00%
New License Agreement \| Minimum \| 2023
MaterialAgreements [Line Items]
Royalty expense					$ 60,000
New License Agreement \| Internally Development Drug Projects
MaterialAgreements [Line Items]
Percentage of royalty on net sales								3.00%
New License Agreement \| Other Parties
MaterialAgreements [Line Items]
Percentage of royalty on net sales								8.00%
George Washington University - Beta2-spectrin siRNA License Agreement
MaterialAgreements [Line Items]
Number of issued patents \| patent										3
Percentage of royalty on net sales										3.00%
License initiation fee										$ 20,000
Accrued portion of annual license fees												10,000
Annual license maintenance fees												20,000
Johns Hopkins University - Mebendazole License Agreement
MaterialAgreements [Line Items]
Number of issued patents \| patent									6
Number of patent applications \| patent									1
Percentage of royalty on net sales									3.50%
Royalty expense												50,000
Accrued royalties												25,000
Number of patients enrolled \| patient									24
Number of patients experiencing adverse effects \| patient									4
Number of patients receiving maximum dose \| patient									15
Four year overall survival rate									25.00%
Upfront license fee									$ 250,000
Payments for other fees									50,000
Payments for royalties									250,000
Johns Hopkins University - Mebendazole License Agreement \| IPO
MaterialAgreements [Line Items]
License fee payment made after IPO						$ 200,000
Johns Hopkins University - Mebendazole License Agreement \| 2022
MaterialAgreements [Line Items]
Royalty expense									5,000
Johns Hopkins University - Mebendazole License Agreement \| 2023
MaterialAgreements [Line Items]
Royalty expense									10,000
Johns Hopkins University - Mebendazole License Agreement \| 2025
MaterialAgreements [Line Items]
Royalty expense									30,000
Johns Hopkins University - Mebendazole License Agreement \| 2026
MaterialAgreements [Line Items]
Royalty expense									50,000
Johns Hopkins University - Mebendazole License Agreement \| 2024
MaterialAgreements [Line Items]
Royalty expense									$ 20,000
Johns Hopkins University - Mebendazole License Agreement \| Maximum
MaterialAgreements [Line Items]
Measurement period									4 years
Johns Hopkins University - Mebendazole License Agreement \| Minimum
MaterialAgreements [Line Items]
Measurement period									2 years
Johns Hopkins University - Prodrug License Agreement
MaterialAgreements [Line Items]
Percentage of royalty on net sales							4.00%
Accrued royalties												2,500
Upfront license fee							$ 100,000
Payments for royalties							150,000
Johns Hopkins University - Prodrug License Agreement \| 2026
MaterialAgreements [Line Items]
Royalty expense							5,000
Johns Hopkins University - Prodrug License Agreement \| 2027
MaterialAgreements [Line Items]
Royalty expense							10,000
Johns Hopkins University - Prodrug License Agreement \| 2028
MaterialAgreements [Line Items]
Royalty expense							20,000
Johns Hopkins University - Prodrug License Agreement \| 2029
MaterialAgreements [Line Items]
Royalty expense							30,000
Johns Hopkins University - Prodrug License Agreement \| 2030
MaterialAgreements [Line Items]
Royalty expense							$ 50,000
Johns Hopkins University - Prodrug License Agreement \| Minimum
MaterialAgreements [Line Items]
Accrued royalties												5,000
Lieber Institute for Brain Development Partnership
MaterialAgreements [Line Items]
Initial term			1 year
Accrued royalties, current												$ 36,000
Feasibility Agreement
MaterialAgreements [Line Items]
Initial term	1 year
Research and development period	3 years